Silviu Itescu, Mesoblast CEO
FDA gives thumbs down for Mesoblast's aGVHD drug, saying one single-arm trial is not enough
Mesoblast’s request for a trading halt Thursday turned out to be a negative.
Late Thursday evening, the Australian company announced that the FDA had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
